Table 2.

Main indications for the use of statins in patients with psoriasis

Patient group	Statin intensitya
Secondary prevention (history of coronary heart disease, vascular brain disease or peripheral arterial disease)	Start high-intensity statin therapy
Primary prevention
(a) Diabetes mellitus	Start moderate/high-intensity statin therapyb
(b) Severe hypercholesterolemia (LDL-C > 190 mg/dl or familial hypercholesterolemia)	Start high-intensity statin therapy
(c) Moderate to severe chronic renal insufficiency without hemodialysis (eGFR between 30 and 59 ml/min/1.73 m2 or < 30 ml/min/1.73 m2, respectively)	Start moderate statin therapy
(d) High cardiovascular risk score (after adjusting for the multiplier factor)	Start high-intensity statin therapy
(e) Moderate risk score (after adjusting for the multiplier factor) with some associated cardiovascular risk factor	Start moderate intensity statin therapy
(f) Subclinical atheromatosis	Start moderate/high-intensity statin therapy

^aHigh-intensity statins: when reducing the LDL-C level ≥ 50% (atorvastatin 40–80 mg/day, rosuvastatin 20–40 mg/day). Moderate intensity statins: when reducing the LDL-C level 30–50% (atorvastatin 10–20 mg/day, rosuvastatin 5–10 mg/day, simvastatin 20–40 mg/day, fluvastatin 80 mg/day, pitavastatin 2–4 mg/day)

^bIn patients with more risk, with associated cardiovascular risk factors or white organ damage, it is reasonable to administer high doses of statins